Short-Term Clinical Benefit of Sirolimus-Eluting Stents Compared to Bare Metal Stents for Patients with Acute Myocardial Infarction

Sirolimus-eluting stents (SES) have been recently proven to reduce restenosis and reintervention compared with bare metal stents (BMS). However, the effectiveness of SES in acute myocardial infarction (AMI) remains uncertain. The aim of this study was to evaluate the efficacy of SES implantation in patients with AMI compared with that of BMS. From January 2003 to April 2004, angioplasty with SES was performed in 76 patients (82 lesions) with AMI and the result was compared with that of 106 patients (113 lesions) treated with BMS. The incidence of major adverse cardiac events (death, nonfatal myocardial infarction, and target lesion revascularization) and binary angiographic restenosis were evaluated. Antiplatelet therapies included aspirin with clopidogrel, or cilostazole. follow-up angiography was performed at sixth month. Baseline demographic characteristics and the incidence of short term adverse events were similar between both SES and BMS groups. At follow-up angiography, SES group showed the significantly lower incidences in adverse events (8.2% vs. 39.3%, p<0.01). late loss (0.38 ± 0.54 mm vs 1.34 ± 0.96 mm, p<0.01) and restenosis (5.9% vs. 35.6%, p<0.01) comparing to BMS group. Therefore, SES implantation could be a safe and effective strategy for the treatment in patients with AMI.